Efficiency of linagliptin on insulin dosage in type 2 diabetes patients
Phase 3
- Conditions
- Type 2 diabetes.Type 2 diabetes mellitus
- Registration Number
- IRCT20210609051526N1
- Lead Sponsor
- Babol University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 96
Inclusion Criteria
Type 2 diabetes
Severe renal failure (GFR below 30)
Age 80 - 18 years
HbA1C between 7 and 10
Exclusion Criteria
Inability to follow the patient
Discontinue insulin or linagliptin
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change insulin dose. Timepoint: At the beginning of the study and at the end of weeks 12 and 24. Method of measurement: Fasting blood sugar test, HBA1c test.
- Secondary Outcome Measures
Name Time Method